BRAF and CTNNB1 mutations are found to be strongly correlated with the pathological subtypes of craniopharyngiomas, which means the diagnosis of pathological subtypes and gene mutations has great significance for the effective adjuvant targeted therapy. This evidence concerns the gene BRAF and craniopharyngioma.